JP2008537673A5 - - Google Patents

Download PDF

Info

Publication number
JP2008537673A5
JP2008537673A5 JP2007553371A JP2007553371A JP2008537673A5 JP 2008537673 A5 JP2008537673 A5 JP 2008537673A5 JP 2007553371 A JP2007553371 A JP 2007553371A JP 2007553371 A JP2007553371 A JP 2007553371A JP 2008537673 A5 JP2008537673 A5 JP 2008537673A5
Authority
JP
Japan
Prior art keywords
antibody
ephb2
seq
hvr
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007553371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008537673A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/003502 external-priority patent/WO2006083936A2/en
Publication of JP2008537673A publication Critical patent/JP2008537673A/ja
Publication of JP2008537673A5 publication Critical patent/JP2008537673A5/ja
Pending legal-status Critical Current

Links

JP2007553371A 2005-01-31 2006-01-31 抗ephb2抗体とその使用方法 Pending JP2008537673A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64854105P 2005-01-31 2005-01-31
US75684406P 2006-01-05 2006-01-05
PCT/US2006/003502 WO2006083936A2 (en) 2005-01-31 2006-01-31 Anti-ephb2 antibodies and methods using same

Publications (2)

Publication Number Publication Date
JP2008537673A JP2008537673A (ja) 2008-09-25
JP2008537673A5 true JP2008537673A5 (enExample) 2009-02-26

Family

ID=36341431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007553371A Pending JP2008537673A (ja) 2005-01-31 2006-01-31 抗ephb2抗体とその使用方法

Country Status (7)

Country Link
US (2) US7767205B2 (enExample)
EP (1) EP1844076A2 (enExample)
JP (1) JP2008537673A (enExample)
AU (1) AU2006210837B2 (enExample)
CA (1) CA2594636A1 (enExample)
NZ (1) NZ556317A (enExample)
WO (1) WO2006083936A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
EP3505191A1 (en) 2004-11-12 2019-07-03 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
AU2006203884B2 (en) * 2005-01-06 2012-02-16 Genentech, Inc. Cancer prognostic, diagnostic and treatment methods
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
WO2007008603A1 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
DK2061510T3 (en) * 2006-08-31 2016-09-05 A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust Treatment and / or prevention of Barrett's esophagus using anti-EphB4 antibody-containing compositions
CL2008002083A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
MX340078B (es) 2009-11-07 2016-06-24 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
HK1208216A1 (en) * 2012-05-15 2016-02-26 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
CA3187392A1 (en) 2013-10-15 2015-04-23 Seagen Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
RU2724530C2 (ru) * 2014-02-06 2020-06-23 Экс4 Фамасьютиклз (Остриэ) ГмбХ Выделенное антитело (варианты), способ получения антитела, выделенная нуклеиновая кислота, экспрессионная кассета (варианты), плазмида (варианты), клетка-хозяин, фармацевтический препарат, набор, способ лечения больного, подверженного риску или страдающего от инфекции e.coli, и способ диагностики определения инфекций e.coli
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
WO2016123412A1 (en) 2015-01-28 2016-08-04 Sorrento Therapeutics, Inc. Antibody drug conjugates
WO2017089606A1 (en) * 2015-11-26 2017-06-01 Kotter Mark Reinhard Therapy to increase remyelination
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
MA43835A (fr) 2016-03-25 2018-11-28 Seattle Genetics Inc Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
WO2017173091A1 (en) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
WO2021255741A1 (en) * 2020-06-17 2021-12-23 4C Biomed Services Ltd. Ephb2 antibody and use thereof in combination therapy
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US7163808B2 (en) * 2000-11-20 2007-01-16 California Institute Of Technology Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
EP1992643A3 (en) * 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1517921B1 (en) * 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
ES2245619T1 (es) * 2002-11-05 2006-01-16 The Regents Of The University Of California Procedimientos y materiales para examinar vias asociadas a la progresion de glioblastoma.
CN107213469A (zh) * 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
EP1740954B1 (en) * 2004-04-07 2015-08-19 Genentech, Inc. Mass spectrometry of antibody conjugates
AU2006203884B2 (en) * 2005-01-06 2012-02-16 Genentech, Inc. Cancer prognostic, diagnostic and treatment methods

Similar Documents

Publication Publication Date Title
JP2008537673A5 (enExample)
JP2008546780A5 (enExample)
RU2423382C1 (ru) Композиции и способы диагностики и лечения опухоли
JP2014509835A5 (enExample)
CN103517719B (zh) 抗体-药物缀合物
JP2013056896A5 (enExample)
US10052382B2 (en) Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides
HK1214161A1 (zh) 抗IL-13受体α2抗体和抗体-药物缀合物
JP2008529497A5 (enExample)
JP2018534933A5 (enExample)
JP2006507013A5 (enExample)
IL290591B2 (en) Antibody drug preparations (ADC) that bind to 191P4D12 proteins
JP2014520088A5 (enExample)
JP2010504755A5 (enExample)
JP2017522861A5 (enExample)
JP2018509146A (ja) Flt3タンパク質に結合する抗体薬物複合体(adc)
JP2014524902A5 (enExample)
RU2007133108A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
JP2014531201A5 (enExample)
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
JP2020522280A5 (enExample)
JP2019205480A5 (enExample)
JP2020522281A5 (enExample)
RU2016118573A (ru) Анти-ly6e антитела и способы применения
RU2012127351A (ru) Композиции и способы для диагностики и лечения опухоли